<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282930</url>
  </required_header>
  <id_info>
    <org_study_id>14-006965</org_study_id>
    <nct_id>NCT02282930</nct_id>
  </id_info>
  <brief_title>Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression</brief_title>
  <official_title>An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to answer whether patients with progressive IgA nephropathy, who
      receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6
      months is effective in inducing improvement in proteinuria and renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With a Complete or Partial Response to Treatment</measure>
    <time_frame>12 Months</time_frame>
    <description>A complete response is defined by &lt;300 mg proteinuria/24 hours and no greater than a 10% reduction in glomerular filtration rate (GFR) as determined by quantified creatinine clearance.
A partial response is defined by &gt;50% reduction in 24 hour proteinuria and no greater than a 25% reduction in baseline GFR as quantified creatinine clearance.
No response is defined by &lt; or equal to 50% reduction, unchanged or increasing proteinuria over baseline levels and a greater than a 25% reduction in baseline GFR as quantified creatinine clearance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects to Develop an Infection</measure>
    <time_frame>12 months</time_frame>
    <description>The number of subjects with infections was defined as the development of pneumonia or complicated urinary tract infection/Pyelonephritis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Progressive IgA Nephropathy</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>ACTH Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injected does of 80 units subcutaneously twice weekly for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTH (Acthar) Gel</intervention_name>
    <description>Injected dose of 80 units subcutaneously twice weekly for 6 months.</description>
    <arm_group_label>ACTH Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Proteinuria &gt; 1000 mg/24h despite documented ACEi/ARB therapy and adequate blood
             pressure control for &gt; 3 months.

          -  Quantified 24h creatinine clearance &gt; 30 ml/min/1.73m2.

          -  Blood pressure &lt; 130/80 mmHg at &gt; 75% of the readings.

          -  Henoch Schoenlein Purpura (HSP): Patients with biopsy proven IgA nephropathy and
             clinical features consistent with Henoch Schonlein Purpura will be considered eligible
             for the study.

          -  Patient must be able to receive injections to be enrolled in the study.

          -  Patient must have a kidney biopsy slide on file - that can be sent to Mayo Clinic.

        Exclusion:

          -  Clinical and histologic evidence of IgA predominant Lupus nephritis

          -  Patients with greater than 50% glomerular senescence or cortical scarring on renal
             biopsy.

          -  Serum Cr &gt; 3.0 mg/dL or creatinine clearance glomerular filtration rate (GFR) &lt; 30
             ml/min at the time of screening

          -  Patients with history of Crohn's disease or Celiac Sprue

          -  Clinical evidence of cirrhosis, chronic active liver disease.

          -  Known infection with hepatitis B, hepatitis C, or HIV (Patients will be serologically
             screened prior to study entry (if the rest has been completed in the last two years,
             the patient will not have to undergo additional testing).

          -  Active systemic infection with bacterial, viral, fungal, or mycobacterial or atypical
             mycobacterial infections (excluding fungal infections of nail beds).

          -  Any major episode of infection requiring hospitalization or treatment with IV
             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to
             screening.

          -  Positive pregnancy test or breast feeding at time of study entry (urine pregnancy test
             will be performed for all women of childbearing potential no later than 7 days prior
             to treatment) or patients unwilling to comply with contraceptive measures as outlined
             above.

          -  Patients receiving therapy with oral prednisone or glucocorticoid equivalent in the
             past 3 months.

          -  Patients who had received immunosuppressive therapy including cyclophosphamide,
             mycophenolate mofetil (MMF), cyclosporine, tacrolimus or azathioprine in the last 6
             months.

          -  Current or recent (within 30 days) exposure to any investigational drug.

          -  Patients having received a live vaccine within 28 days of study enrollment.

          -  Hemoglobin: &lt; 8.5 gm/dL

          -  Platelets: &lt; 100,000/mm

          -  Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) &gt; 2.5 x Upper Limit
             of Normal

          -  Patients with anaphylaxis and/or known allergic reactions to ACTH

          -  Previous Treatment with ACTH

          -  History of drug, alcohol, or chemical abuse within 6 months prior to screening

          -  Concomitant or previous malignancies, with the exception of adequately treated basal
             or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

          -  History of psychiatric disorder that would interfere with normal participation in this
             protocol.

          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease).

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complication.

          -  Inability to comply with study and follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Fervenza, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <results_first_submitted>June 4, 2019</results_first_submitted>
  <results_first_submitted_qc>June 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2019</results_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Fernando Fervenza</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ACTH</keyword>
  <keyword>Acthar</keyword>
  <keyword>IgA</keyword>
  <keyword>Progressive</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02282930/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acthar (ACTH) Gel</title>
          <description>Injected does of 80 units subcutaneously twice weekly for 6 months.
Acthar (ACTH) Gel: Injected dose of 80 units subcutaneously twice weekly for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACTH Gel</title>
          <description>Injected does of 80 units subcutaneously twice weekly for 6 months.
ACTH (Acthar) Gel: Injected dose of 80 units subcutaneously twice weekly for 6 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Complete or Partial Response to Treatment</title>
        <description>A complete response is defined by &lt;300 mg proteinuria/24 hours and no greater than a 10% reduction in glomerular filtration rate (GFR) as determined by quantified creatinine clearance.
A partial response is defined by &gt;50% reduction in 24 hour proteinuria and no greater than a 25% reduction in baseline GFR as quantified creatinine clearance.
No response is defined by &lt; or equal to 50% reduction, unchanged or increasing proteinuria over baseline levels and a greater than a 25% reduction in baseline GFR as quantified creatinine clearance.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acthar (ACTH) Gel</title>
            <description>Injected does of 80 units subcutaneously twice weekly for 6 months.
ACTH (Acthar) Gel: Injected dose of 80 units subcutaneously twice weekly for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Complete or Partial Response to Treatment</title>
          <description>A complete response is defined by &lt;300 mg proteinuria/24 hours and no greater than a 10% reduction in glomerular filtration rate (GFR) as determined by quantified creatinine clearance.
A partial response is defined by &gt;50% reduction in 24 hour proteinuria and no greater than a 25% reduction in baseline GFR as quantified creatinine clearance.
No response is defined by &lt; or equal to 50% reduction, unchanged or increasing proteinuria over baseline levels and a greater than a 25% reduction in baseline GFR as quantified creatinine clearance.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects to Develop an Infection</title>
        <description>The number of subjects with infections was defined as the development of pneumonia or complicated urinary tract infection/Pyelonephritis</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acthar (ACTH) Gel</title>
            <description>Injected does of 80 units subcutaneously twice weekly for 6 months.
ACTH (Acthar) Gel: Injected dose of 80 units subcutaneously twice weekly for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects to Develop an Infection</title>
          <description>The number of subjects with infections was defined as the development of pneumonia or complicated urinary tract infection/Pyelonephritis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be collected from baseline until the completion of the final study visit for each subject, approximately 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACTH Gel</title>
          <description>Injected does of 80 units subcutaneously twice weekly for 6 months.
ACTH (Acthar) Gel: Injected dose of 80 units subcutaneously twice weekly for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Soreness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fernando Fervenza</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-1045</phone>
      <email>fervenza.fernando@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

